Literature DB >> 27073569

c-MET inhibition enhances the response of the colorectal cancer cells to irradiation in vitro and in vivo.

Yitao Jia1, Guangyao Dai2, Jinxi Wang3, Xing Gao4, Zhaolong Zhao5, Zhihui Duan5, Bin Gu5, Weiguang Yang5, Jianhua Wu6, Yingchao Ju6, Mingxia Wang7, Zhongxin Li5.   

Abstract

The aim of the present study was to investigate the effect of hepatocyte growth factor receptor (c-MET) inhibition on the viability of colon cancer cells and xenografts exposed to irradiation using short hairpin (sh)RNA or the c-MET inhibitor PHA665752. The underlying mechanisms were also investigated. Human colorectal adenocarcinoma HT-29 cells were infected with a lentivirus expressing shRNAs against c-MET and were irradiated at 0, 2, 4, 6 and 8 Gy. The viability of the cells was assessed by alamarBlue® assays. Mice bearing human colon carcinoma SW620 xenografts were randomly selected to receive 2.5% dimethyl sulfoxide (DMSO), 25 mg/kg PHA665752 intraperitoneally once every 2 days for 3 weeks, irradiation at 10 Gy, or 25 mg/kg PHA665752 intraperitoneally once every 2 days for 3 weeks followed 24 h later by irradiation at 10 Gy. The mean tumor volume (MTV) was measured. The apoptotic rate of cells was detected by terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assays, and double stranded break marker antibody γ-H2AX and hypoxia inducible factor (HIF)-1α expression was examined by immunohistochemistry. alamarBlue assays revealed that c-MET downregulation by shRNA markedly accentuated the irradiation-induced reduction in the viability of HT-29 cells compared with HT-29 cells irradiated at the same doses (P<0.05). A combination of irradiation and PHA665752 caused an additional reduction in the MTV (382.8±42.4 mm3; P<0.01 vs. irradiation and PHA665752, 998.0±180.6 and 844.8±190.0 mm3, respectively). TUNEL assays revealed that irradiation and PHA665752 alone caused significant apoptosis of the SW620 cells in the tumor xenografts (P<0.01 vs. DMSO). The apoptotic index in the tumor xenografts of mice treated with a combination of irradiation and PHA665752 was significantly increased compared with mice treated with either agent alone (P<0.01). The combination of irradiation and PHA665752 was also associated with a marked increase in γ-H2AX levels and a significant decrease in HIF-1α expression in the xenografts (P<0.01). In conclusion, c-MET inhibition sensitizes colorectal cancer cells to irradiation by enhancing the formation of DNA double strand breaks and possibly alleviating tumor hypoxia.

Entities:  

Keywords:  c-MET inhibitor; colorectal cancer; radiation; sensitivity; small interfering RNA

Year:  2016        PMID: 27073569      PMCID: PMC4812355          DOI: 10.3892/ol.2016.4303

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  34 in total

1.  Chemotherapy with preoperative radiotherapy in rectal cancer.

Authors:  Jean-François Bosset; Laurence Collette; Gilles Calais; Laurent Mineur; Philippe Maingon; Ljiljana Radosevic-Jelic; Alain Daban; Etienne Bardet; Alexander Beny; Jean-Claude Ollier
Journal:  N Engl J Med       Date:  2006-09-14       Impact factor: 91.245

2.  The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells.

Authors:  James W Welsh; Daruka Mahadevan; Ron Ellsworth; Laurence Cooke; David Bearss; Baldassarre Stea
Journal:  Radiat Oncol       Date:  2009-12-22       Impact factor: 3.481

3.  A novel panel of biomarkers predicts radioresistance in patients with squamous cell carcinoma of the head and neck.

Authors:  Jan Akervall; Sirisha Nandalur; Jacob Zhang; Chao-Nan Qian; Neal Goldstein; Paulina Gyllerup; Ylva Gardinger; Jens Alm; Katarina Lorenc; Karolina Nilsson; James Resau; George Wilson; Bin Teh
Journal:  Eur J Cancer       Date:  2013-12-09       Impact factor: 9.162

4.  Prognostic importance of Mandard tumour regression grade following pre-operative chemo/radiotherapy for locally advanced rectal cancer.

Authors:  A S Dhadda; P Dickinson; A M Zaitoun; N Gandhi; E M Bessell
Journal:  Eur J Cancer       Date:  2011-01-08       Impact factor: 9.162

5.  Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.

Authors:  Jean-Pierre Gérard; Thierry Conroy; Franck Bonnetain; Olivier Bouché; Olivier Chapet; Marie-Thérèse Closon-Dejardin; Michel Untereiner; Bernard Leduc; Eric Francois; Jean Maurel; Jean-François Seitz; Bruno Buecher; Rémy Mackiewicz; Michel Ducreux; Laurent Bedenne
Journal:  J Clin Oncol       Date:  2006-10-01       Impact factor: 44.544

6.  MET Inhibition Results in DNA Breaks and Synergistically Sensitizes Tumor Cells to DNA-Damaging Agents Potentially by Breaching a Damage-Induced Checkpoint Arrest.

Authors:  Michaela Medová; Daniel Matthias Aebersold; Wieslawa Blank-Liss; Bruno Streit; Matúš Medo; Stefan Aebi; Yitzhak Zimmer
Journal:  Genes Cancer       Date:  2010-10

Review 7.  Receptor signaling as a regulatory mechanism of DNA repair.

Authors:  Raymond E Meyn; Anapama Munshi; John V Haymach; Luka Milas; K Kian Ang
Journal:  Radiother Oncol       Date:  2009-07-15       Impact factor: 6.280

8.  Adenoviral mediated hepatocyte growth factor gene attenuates hyperglycemia and beta cell destruction in overt diabetic mice.

Authors:  Mi-Kyoung Park; Duk-Kyu Kim; Hye-Jeong Lee
Journal:  Exp Mol Med       Date:  2003-12-31       Impact factor: 8.718

9.  Scatter factor protects epithelial and carcinoma cells against apoptosis induced by DNA-damaging agents.

Authors:  S Fan; J A Wang; R Q Yuan; S Rockwell; J Andres; A Zlatapolskiy; I D Goldberg; E M Rosen
Journal:  Oncogene       Date:  1998-07-16       Impact factor: 9.867

10.  Clinicopathologic significance of CXCR4 and Nrf2 in colorectal cancer.

Authors:  Tinghua Hu; Yu Yao; Shuo Yu; Hui Guo; Lili Han; Wenjuan Wang; Tao Tian; Yibin Hao; Zhiyan Liu; Kejun Nan; Shuhong Wang
Journal:  J Biomed Res       Date:  2013-07-06
View more
  8 in total

1.  Genome-wide investigation of gene-cancer associations for the prediction of novel therapeutic targets in oncology.

Authors:  Adrián Bazaga; Dan Leggate; Hendrik Weisser
Journal:  Sci Rep       Date:  2020-07-01       Impact factor: 4.379

Review 2.  Emerging actionable targets to treat therapy-resistant colorectal cancers.

Authors:  Emanuela Grassilli; Maria Grazia Cerrito
Journal:  Cancer Drug Resist       Date:  2022-01-04

3.  Survival of HT29 cancer cells is influenced by hepatocyte growth factor receptor inhibition through modulation of self-DNA-triggered TLR9-dependent autophagy response.

Authors:  Bettina Bohusné Barta; Ágnes Simon; Lőrinc Nagy; Titanilla Dankó; Regina Eszter Raffay; Gábor Petővári; Viktória Zsiros; Anna Sebestyén; Ferenc Sipos; Györgyi Műzes
Journal:  PLoS One       Date:  2022-05-12       Impact factor: 3.752

Review 4.  Opportunities and challenges of targeting c-Met in the treatment of digestive tumors.

Authors:  Zhengchao Zhang; Dong Li; Heng Yun; Jie Tong; Wei Liu; Keqiang Chai; Tongwei Zeng; Zhenghua Gao; Yongqiang Xie
Journal:  Front Oncol       Date:  2022-08-01       Impact factor: 5.738

5.  Verticillin A inhibits colon cancer cell migration and invasion by targeting c-Met.

Authors:  Qian-Qian Liu; Xue-Li Zeng; Yue-Lin Guan; Jing-Xin Lu; Kai Tu; Fei-Yan Liu
Journal:  J Zhejiang Univ Sci B       Date:  2020-10       Impact factor: 3.066

6.  A five-gene based risk score with high prognostic value in colorectal cancer.

Authors:  Yida Pan; Hongyang Zhang; Mingming Zhang; Jie Zhu; Jianghong Yu; Bangting Wang; Jigang Qiu; Jun Zhang
Journal:  Oncol Lett       Date:  2017-09-28       Impact factor: 2.967

7.  ITGA7 functions as a tumor suppressor and regulates migration and invasion in breast cancer.

Authors:  Adheesh Bhandari; Erjie Xia; Yuying Zhou; Yaoyao Guan; Jingjing Xiang; Lingguo Kong; Yinghao Wang; Fan Yang; Ouchen Wang; Xiaohua Zhang
Journal:  Cancer Manag Res       Date:  2018-05-01       Impact factor: 3.989

Review 8.  HGF/c-MET: A Promising Therapeutic Target in the Digestive System Cancers.

Authors:  Hongli Zhang; Qingqing Feng; Wei-Dong Chen; Yan-Dong Wang
Journal:  Int J Mol Sci       Date:  2018-10-23       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.